目的：观察非诺特罗与异丙托溴铵溶液联合雾化吸入缓解重度慢性阻塞性肺病(COPD)稳定期患者气流阻塞的功效和临床安全性。方法：选择重度COPD稳定期患者42例，随机分为非诺特罗组(A组)、异丙托溴铵组(B组)及联合用药组(C组)。分别测定各组用药前及用药后30、60、120min肺通气功能用力肺活量(FVC)、第1秒用力呼气量(FEV1)、最大呼气中期流速(FEF25%～75%)、最大呼气流速(PEF)。结果：三组患者用药后肺通气功能FVC、FEV1、FEF25%～75%、PEF峰值均较用药前有明显增量，与基础肺功能比较差异均有显著性(P＜0.01)。而C组峰值均数与A、B组峰值均数比较差异均有显著性(P＜0.01)。三组均无严重不良反应。结论：对重度COPD稳定期患者在常规治疗下雾化吸入支气管扩张剂能改善其临床气促症状，而联合应用非诺特罗和异丙托溴铵疗效优于任何一药单独应用。%Objective:To observe the effects of nebulized inhalant ofcombined fenoteral and ipratropium bromide on the relief of air flow obstruction and its clinical safety in severe COPD patients.Methods:Forty-two severe COPD patients in stable stage were selected and randomly divided into 3 groups:fenoterol group(A),ipratropium bromide group(B),fenoterol combined ipratropium bromide group(C).The lung function(FVC,FEV1，FEF25%～75%,PEF) at 30,60 and 120 min,before and after the administration in 3 groups were measured.At the same time,the side effects of drugs were recorded.Results:In group A,B and C,the peak values of the lung function(FVC,FEV-1,FEF25%～75%,PEF) increased significantly after administration(P＜0.01).The average peak values of the lung function in the C group increased significantly in comparison with those in the A and B groups(P＜0.01).No severe adverse effect was found in any of the 3 groups.Conclusions:These bronchodilator agents routinely used can improve the symptom of dyspnea in severe COPD patients at stable stage,but the effects of combined administration of fenoterol and ipratropium bromide are obviously more satisfactory.
展开▼
